1-Hydroxybenzotriazole → 2-(1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-5-yl)-N-[4-(4-isobutylphenyl)-1,3-thiazol-2-yl]acetamide

HRID 877029

Reaktionsgleichung

Reaktionsgleichung von HRID 877029
[CH3:1][N:2]1[C:7]2=[CH:8][S:9][C:10](C)=[C:6]2[C:5](=[O:12])[N:4]([CH3:13])[C:3]1=[O:14].[CH2:15]([C:19]1[CH:24]=[CH:23][C:22]([C:25]2[N:26]=[C:27]([NH2:30])[S:28][CH:29]=2)=[CH:21][CH:20]=1)[CH:16]([CH3:18])[CH3:17].CCN=C=NC[CH2:37][CH2:38]N(C)C.Cl.C1C=CC2N([OH:52])N=NC=2C=1>CN(C1C=CN=CC=1)C.ClCCCl>[CH3:1][N:2]1[C:10]2[S:9][CH:8]=[C:7]([CH2:37][C:38]([NH:30][C:27]3[S:28][CH:29]=[C:25]([C:22]4[CH:21]=[CH:20][C:19]([CH2:15][CH:16]([CH3:18])[CH3:17])=[CH:24][CH:23]=4)[N:26]=3)=[O:52])[C:6]=2[C:5](=[O:12])[N:4]([CH3:13])[C:3]1=[O:14]

Komponenten

7

Versuchsvorschrift

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (100 mg, 0.393 mmol) with 4-(4-isobutylphenyl)-1,3-thiazol-2-amine (91 mg, 0.393 mmol) in the presence of EDCI hydrochloride (90 mg, 0.472 mmol), HOBt (16 mg, 0.117 mmol) and DMAP (5 mg, 0.039 mmol) in 1,2 dichloroethane (4 ml) to give 42 mg of the product as a white solid; 1H NMR (300 MHz, CDCl3) δ 0.88 (d, J=6.3 Hz, 6H), 1.83-1.90 (m, 1H), 2.48 (d, J=6.9 Hz, 2H), 3.51 (s, 3H), 3.57 (s, 3H), 4.06 (s, 2H), 6.88 (s, 1H), 7.04 (s, 1H), 7.16 (d, J=7.8 Hz, 2H), 7.72 (d, J=7.8 Hz, 2H), 10.73 (br s, 1H); APCI-MS (m/z) 469.14 (M+H)+.

Quellen und Nachweise

ORD-Eintrag
ord-ac3f929e76f54bce85f160a3c00cc5e2
Quelldatensatz
uspto-grants-2015_03
Patentnummer
US08987278B2

Verknüpfte Notizen

Wird geladen…